FUNCTIONS OF IN VITRO PHARMACODYNAMIC MODELS OF INFECTION IN ANTIMICROBIAL DEVELOPMENT
OBJECTIVES FOR TODAY
TYPES OF MODEL SYSTEM
Main advantages
ANTIBACTERIAL EFFECT MEASURES (END POINTS)
ANTIBACTERIAL EFFECT MEASURED BY AREAS
COMPARISON OF ANTIBACTERIAL EFFECT MEASURES
HOW AREA MEASURES VARY OVER LOG AUC/MIC WITH CIPROFLOXACIN (RANGE 7.6 - 7690)
HOW TO DECIDE THE BEST ANTIBACTERIAL EFFECT MEASURE
ANTIBACTERIAL EFFECT MEASURES MOXIFLOXACIN 400mg OD FOR 48H
DESCRIPTIVE STUDIES WITH MOXIFLOXACIN AND S. PNEUMONIAE
ANTIBACTERIAL EFFECT MEASURES - GEMIFLOXACIN AND S. PNEUMONIAE
ANTIBACTERIAL EFFECT OF GEMIFLOXACIN AGAINST S. PNEUMONIAE
DESCRIPTIVE STUDIES MOXIFLOXACIN 400MG d 24h, S. PNEUMONIAE (n=4), H. INFLUENZAE (n=4), M. CATARRHALIS (n=2), B. HAEMOLYTIC STREPTOCOCCI (n=2), S. AUREUS (n=2)
DESCRIPTIVE ANALYSIS
EMERGENCE OF RESISTANCE
QUINOLONE PD AND EMERGENCE OF RESISTANCE
QUINOLONE PD AND ANTIBACTERIAL EFFECT
ANALYTICAL APPROACHES (1) - QUINOLONES
ANALYTICAL APPROACHES (2)
IS AUC/MIC THE WHOLE STORY ? Comparison of antibacterial effect measures of 1g 24h od ciprofloxacin and 500g 12h bd ciprofloxacin
FUTURE ROLE OF IN VITRO PD MODELS IN DRUG DEVELOPMENT (1)
FUTURE ROLE OF IN VITRO PD MODELS IN DRUG DEVELOPMENT (2)
Email: webmaster@isap.org
Home Page: http://www.isap.org/Birmingham-1999.htm